Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Other Working Capital Changes (2021 - 2025)

Kiniksa Pharmaceuticals International's Other Working Capital Changes history spans 5 years, with the latest figure at $25.0 million for Q4 2025.

  • For Q4 2025, Other Working Capital Changes rose 711.99% year-over-year to $25.0 million; the TTM value through Dec 2025 reached $22.5 million, up 664.28%, while the annual FY2025 figure was $22.5 million, 664.28% up from the prior year.
  • Other Working Capital Changes reached $25.0 million in Q4 2025 per KNSA's latest filing, up from -$760000.0 in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $25.0 million in Q4 2025 to a low of -$11.7 million in Q4 2022.
  • Average Other Working Capital Changes over 5 years is $748700.0, with a median of -$351000.0 recorded in 2021.
  • Peak YoY movement for Other Working Capital Changes: soared 3041.18% in 2022, then plummeted 4598.85% in 2024.
  • A 5-year view of Other Working Capital Changes shows it stood at -$615000.0 in 2021, then plummeted by 1807.8% to -$11.7 million in 2022, then soared by 99.26% to -$87000.0 in 2023, then tumbled by 4598.85% to -$4.1 million in 2024, then skyrocketed by 711.99% to $25.0 million in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Other Working Capital Changes are $25.0 million (Q4 2025), -$760000.0 (Q3 2025), and -$7.1 million (Q2 2025).